KU Leuven Department of Human Genetics, Laboratory for Complex Genetics, Leuven, Belgium.
KU Leuven Department of Chronic Diseases, Metabolism and Ageing, Translational Research Center for Gastrointestinal Disorders (TARGID), Leuven, Belgium.
Expert Opin Ther Targets. 2019 Nov;23(11):943-954. doi: 10.1080/14728222.2019.1677608. Epub 2019 Oct 15.
: Given the high rate of primary and acquired resistance to current inflammatory bowel disease (IBD) treatments, novel drug targets and biomarkers that aid in therapeutic prediction are eagerly awaited. Furthermore, postponing treatment initiation because of a diagnostic delay profoundly affects patient well-being and overall disease evolution. Among the emerging targets and biomarkers, oncostatin M (OSM) has gained much interest in the past few years.: A literature search to June 2019 was performed to identify the most relevant reports on Oncostatin M. The authors summarize the biology of OSM, its role in health and disease, its potential as a diagnostic, prognostic and therapeutic biomarker in the field of IBD and how it might be a drug target of the future.: OSM has diagnostic, prognostic and therapeutic capabilities. High mucosal predicts primary non-response to anti-TNF antibodies. However, one could question whether a single cytokine can capture the complexity and heterogeneity of IBD. Neutralizing OSM in patients with elevated mucosal appears to be attractive and should be considered as a valid option for the first biomarker-stratified, proof-of-concept trial that studies a novel therapeutic compound in IBD.
: 鉴于当前炎症性肠病 (IBD) 治疗方法的原发性和获得性耐药率很高，人们急切期待新的药物靶点和生物标志物来辅助治疗预测。此外，由于诊断延迟而推迟治疗开始会严重影响患者的健康和整体疾病进展。在新兴的靶点和生物标志物中，近年来，肿瘤坏死因子（OSM）引起了广泛关注。: 作者进行了截至 2019 年 6 月的文献检索，以确定关于肿瘤坏死因子的最相关报告。作者总结了 OSM 的生物学特性、它在健康和疾病中的作用、它作为 IBD 领域诊断、预后和治疗生物标志物的潜力，以及它如何成为未来药物的靶点。: OSM 具有诊断、预后和治疗能力。高黏膜 预测对抗 TNF 抗体的原发性无反应。然而，人们可能会质疑单一细胞因子是否可以捕捉 IBD 的复杂性和异质性。在黏膜 升高的患者中中和 OSM 似乎很有吸引力，并且应该被认为是在 IBD 中研究新型治疗化合物的首个基于生物标志物的概念验证试验的有效选择。
